InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Harris Matthew Scott, Directeur Médical. Officer active across 1 companies, notably Altimmune, Inc.. Aggregated, 5 filings have been published. The latest transaction was filed on 28 February 2022 — Levée d'options. Regulator: SEC (Form 4). The full history is openly available.
Declarations5 total
€51,55130,000 shares@ €1.71840.0093% mcap62.0% of flow
Common Stock, par value $0.0001
SEC:0001104659-22-029462:0·
€11,0721,800 shares@ €6.151270.2% of flow
Common Stock, par value $0.0001
SEC:0001104659-22-011519·
€11,0721,800 shares@ €6.15120.0020% mcap13.3% of flow
Common Stock, par value $0.0001
SEC:0001104659-22-011519:0·
€4,700725 shares@ €6.482429.8% of flow
Common Stock, par value $0.0001
SEC:0001104659-21-101663·
€4,700725 shares@ €6.48240.0008% mcap5.7% of flow
Common Stock, par value $0.0001
SEC:0001104659-21-101663:0·
5 of 5 declarations
About Harris Matthew Scott
Matthew Scott Harris is the Chief Medical Officer at Altimmune, Inc. He is responsible for leading medical and research initiatives. Matthew plays a key role in developing new treatments and improving patient outcomes.
